RARE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RARE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-15), Ultragenyx Pharmaceutical's current share price is $40.97. Ultragenyx Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.88. Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio for today is 10.56.
The historical rank and industry rank for Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Ultragenyx Pharmaceutical's highest Cyclically Adjusted PS Ratio was 28.85. The lowest was 8.75. And the median was 12.53.
RARE's Cyclically Adjusted PS Ratio is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Ultragenyx Pharmaceutical's adjusted revenue per share data for the three months ended in Mar. 2024 was $1.291. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.88 for the trailing ten years ended in Mar. 2024.
The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 11.41 | 12.62 | 9.49 | 12.47 | 12.02 |
For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 40.97 | / | 3.88 | |
= | 10.56 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Ultragenyx Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 1.291 | / | 129.4194 | * | 129.4194 | |
= | 1.291 |
Current CPI (Mar. 2024) = 129.4194.
Ultragenyx Pharmaceutical Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.003 | 101.861 | 0.004 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.000 | 102.862 | 0.000 |
201706 | 0.000 | 103.349 | 0.000 |
201709 | 0.005 | 104.136 | 0.006 |
201712 | 0.056 | 104.011 | 0.070 |
201803 | 0.218 | 105.290 | 0.268 |
201806 | 0.257 | 106.317 | 0.313 |
201809 | 0.234 | 106.507 | 0.284 |
201812 | 0.320 | 105.998 | 0.391 |
201903 | 0.342 | 107.251 | 0.413 |
201906 | 0.420 | 108.070 | 0.503 |
201909 | 0.447 | 108.329 | 0.534 |
201912 | 0.616 | 108.420 | 0.735 |
202003 | 0.626 | 108.902 | 0.744 |
202006 | 1.009 | 108.767 | 1.201 |
202009 | 1.342 | 109.815 | 1.582 |
202012 | 1.415 | 109.897 | 1.666 |
202103 | 1.481 | 111.754 | 1.715 |
202106 | 1.286 | 114.631 | 1.452 |
202109 | 1.203 | 115.734 | 1.345 |
202112 | 1.216 | 117.630 | 1.338 |
202203 | 1.150 | 121.301 | 1.227 |
202206 | 1.278 | 125.017 | 1.323 |
202209 | 1.295 | 125.227 | 1.338 |
202212 | 1.473 | 125.222 | 1.522 |
202303 | 1.428 | 127.348 | 1.451 |
202306 | 1.528 | 128.729 | 1.536 |
202309 | 1.368 | 129.860 | 1.363 |
202312 | 1.569 | 129.419 | 1.569 |
202403 | 1.291 | 129.419 | 1.291 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Emil D Kakkis | director, 10 percent owner, officer: President & CEO | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Thomas Richard Kassberg | officer: CBO & Senior Vice President | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Howard Horn | officer: Chief Financial Officer | C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Theodore Alan Huizenga | officer: Controller and PAO | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Erik Harris | officer: EVP & Chief Commercial Officer | 60 LEVERONI COURT, NOVATO CA 94949 |
Sanders Corazon (corsee) D. | director | C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729 |
John Richard Pinion | officer: See Remarks | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Karah Herdman Parschauer | officer: EVP and General Counsel | 60 LEVERONI COURT, NOVATO CA 94949 |
Eric Crombez | officer: EVP and Chief Medical Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Dennis Karl Huang | officer: SVP and Chief Tech Ops Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Camille L Bedrosian | officer: EVP and Chief Medical Officer | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Mardi Dier | officer: CFO & Executive Vice President | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Amrit Ray | director | 60 LEVERONI COURT, NOVATO CA 94949 |
William Aliski | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Shalini Sharp | officer: CFO & Senior Vice President | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
From GuruFocus
By GlobeNewswire • 09-25-2023
By Marketwired • 07-31-2023
By Marketwired • 09-20-2023
By GlobeNewswire • 10-12-2023
By Marketwired • 10-14-2023
By Marketwired • 10-23-2023
By Marketwired • 07-12-2023
By Marketwired • 10-05-2023
By Marketwired • 10-26-2023
By GlobeNewswire • 10-19-2023